Ligand Pharmaceuticals
ISIN US53220K5048
|WKN A1C9RN
Overview
Description
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 1,769.82 m |
| EPS, EUR | -0.14 |
| P/B ratio | 2.41 |
| P/E ratio | 46.02 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 154.51 m |
| Net income, EUR | -3.73 m |
| Profit margin | -2.41% |
What ETF is Ligand Pharmaceuticals in?
There are 27 ETFs which contain Ligand Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Ligand Pharmaceuticals is the L&G Pharma Breakthrough UCITS ETF.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
